Machado Meyer Advogados and Seixas Coelho e Pereira Coelho Advogados acted as legal advisor on the deal. Neuraxpharm, a leading European specialty pharmaceutical company focused on...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Neuraxpharm on the deal. Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders on the sale of Spanish pharmaceutical...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Neuraxpharm Group on the deal. Neuraxpharm Group acquired two portfolios of established products from Sanofi which are marketed globally in more than...
You must be a Standard 1 Year member to access this content.
